Trial Profile
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Varespladib (Primary)
- Indications Acute lung injury
- Focus Adverse reactions
- Acronyms IMPACTS
- Sponsors Anthera Pharmaceuticals
- 27 May 2014 New trial record
- 29 Apr 2010
- 15 Oct 2009